Biosergen AB (publ) (STO:BIOSGN)

Sweden flag Sweden · Delayed Price · Currency is SEK
9.10
-0.70 (-7.14%)
May 21, 2026, 12:20 PM CET
Market Cap23.01M -67.2%
Revenue (ttm)n/a
Net Income-40.82M
EPS-17.38
Shares Out2.35M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,056
Average Volume1,827
Open9.50
Previous Close9.80
Day's Range9.10 - 9.50
52-Week Range9.10 - 67.80
Beta-0.03
RSI22.73
Earnings DateMay 6, 2026

About Biosergen AB

Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 1
Stock Exchange Nasdaq Stockholm
Ticker Symbol BIOSGN
Full Company Profile

Financial Performance

Financial Statements

News

Biosergen AB Quarterly report: Q4 2025

Biosergen AB has published its Q4 2025 quarterly earnings report on February 10, 2026.

3 months ago - Filings

Biosergen AB Quarterly report: Q3 2025

Biosergen AB has published its Q3 2025 quarterly earnings report on November 19, 2025.

6 months ago - Filings

Biosergen AB Quarterly report: Q2 2025

Biosergen AB has published its Q2 2025 quarterly earnings report on August 20, 2025.

9 months ago - Filings

Biosergen AB Quarterly report: Q1 2025

Biosergen AB has published its Q1 2025 quarterly earnings report on May 21, 2025.

1 year ago - Filings